1. Introduction {#s0005}
===============

Dendritic cells (DCs) present antigenic peptides on MHC I and class II molecules resulting in stimulation of CD8^+^ and CD4^+^ T cells, respectively. This ability to activate both CD4 and CD8 T cell responses is the basis for the effectiveness of DC-based vaccines in prophylaxis against infections including HIV, *Streptococcus pneumonia*, *Chlamydia trachomatis* or *Mycobacterium* ([@bb0225], [@bb0030], [@bb0195], [@bb0105], [@bb0075]).

Groups at risk of listeriosis include pregnant women, neonates, the elderly and immune-compromised patients. DC vaccines loaded *ex vivo* with peptides and injected back into the host, are highly effective at inducing cellular immunity and thereby could be useful for *Listeria* immunization ([@bb0235]).

The objective of this study was to find a simple method to predict the minimum epitope requirements for a DC vaccine against human listeriosis and involved testing DC vaccines in mice susceptible or resistant to *Listeria*. C57BL/6 mice have a *Listeria* resistant allele at the *Hc* locus on chromosome 2 and show reduced susceptibility to intravenous, *i*.*v*., intragastric, *i*.*g*. or intraperitoneal, *i*.*p*, challenge with *Listeria* when compared to susceptible Balb/c mice ([@bb0145], [@bb0190]). Therefore, we used C57BL/6 mice to mimic the population at low risk of listeriosis, while Balb/c mice were used to mimic high-risk groups. Two *Listeria* antigens were selected as the focus of our study, listeriolysin O (LLO) and the glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) as they have previously been shown to elicit strong CD4^+^ and CD8^+^ T cell responses ([@bb0005], [@bb0020], [@bb0025]). This was important as human listeriosis is not well characterised and antigens other than LLO or GAPDH that induce cellular immunity have yet to be found ([@bb0010]; CAD and RCG unpublished results).

Bioinformatic methods that predict T cell epitopes *via* their ability to bind MHC molecules provide a faster and less costly alternative to strategies for selection of T-cell vaccine candidates such as MHC peptide elution or assays to map T-cell epitopes using complete sets of overlapping peptides ([@bb0080], [@bb0215]). This is especially relevant given the limited current data on *Listeria* epitopes ([@bb0240]).

Another challenge when developing T-cell vaccines is the restricted ability of soluble antigens to stimulate strong T-cell responses, which at least in part reflects the lack of MHC class I cross-presentation of such antigens. Hence to maximise T-cell responses against *Listeria* an adjuvant is needed to up-regulate presentation of antigen on MHC class I and class II molecules on the surface of antigen presenting cells. Advax™ is a novel polysaccharide adjuvant derived from microparticles of delta β-[d]{.smallcaps}-\[2-1\]poly(fructo-furanosyl)α-[d]{.smallcaps}-glucose (delta inulin) ([@bb0035], [@bb0040], [@bb0045], [@bb0050]). Advantages of Advax include the fact that it has already been shown to be well tolerated, effective and safe for human use ([@bb0085], [@bb0090]), but most importantly for the current study, its demonstrated ability to induce potent CD4^+^ and CD8^+^ T cell responses against a wide variety of exogenous antigens including proteins from Japanese encephalitis, influenza, hepatitis B, HIV, and SARS coronavirus ([@bb0140], [@bb0055], [@bb0205], [@bb0100]). Hence, Advax adjuvant had ideal properties for use in our *Listeria* T-cell epitope screening programme.

We present a method that combines bioinformatics and structural predictions of peptide binding to MHC class I and class II molecules with convenient T-cell readouts. Vaccine predictions were validated *in vivo* and immunological parameters checked to confirm vaccine efficiency.

2. Methods {#s0010}
==========

2.1. Cells {#s0015}
----------

Mice were 8--12 week-old female Balb/c from Charles River (France) or C57BL/6 from our animal facility. DCs were obtained from femur bone-marrow, differentiated with GM-CSF, and CD11c^+^ cells isolated with anti-mouse CD11c-coated magnetic beads and MACS™ separation columns (Miltenyi Biotech Inc., Auburn, CA) ([@bb0115], [@bb0020]). DCs used were MHC-II^+^CD11c^+^CD40^+^CD11b^+/−^CD86^+/−^F4/80^−^Gr-1^−^.

2.2. Peptides and adjuvants {#s0020}
---------------------------

We used GAPDH~1--15~, GAPDH~1--22~, LLO~91--99~, LLO~296--304~, LLO~189--201~, LLO~189--200~ and LLO~190--201~ peptides. Peptides were synthesized at CNB (CSIC, Madrid) followed by HPLC and mass spectrometry using a MALDI-TOF Reflex™ IV mass spectrometer (Bruker Daltonics, Bremen, Germany). Peptide purity was \> 95% after HPLC. Advax™ adjuvant (Adv1) was supplied by Vaxine (Adelaide, Australia) and was mixed with antigen by simple admixture immediately before immunization of mice or *in vitro* analysis.

2.3. Bacteria {#s0025}
-------------

*Listeria monocytogenes* 10403S strain (LM^WT^) was obtained from D.A. Portnoy (University of California, Berkeley, CA, USA).

2.4. Preparation of peptide pulsed DC vaccines {#s0030}
----------------------------------------------

Cultured DCs were *ex vivo* loaded with 50 μg/ml of GAPDH~1--15~, GAPDH~1--22~, LLO~91--99~, LLO~296--304~, LLO~189--200~, LLO~190--201~ or LLO~189--201~ peptides for 24 h in the presence of 50 μg/ml of Advax. Supernatants were collected and stored at − 80 °C for cytokine measurements. Cells were analysed for cell surface markers by FACS.

2.5. Measurement of viability and apoptosis {#s0035}
-------------------------------------------

Cultured DCs were also analysed for viability incubating cells with Trypan-blue. Cells stained with Trypan-blue were considered dead cells, while cells non-stained with the dye were viable. Cells were counted in a Neubauer haemocytometer and results were expressed as the mean of the percentages of viable cells ± SD. DCs were also examined for apoptosis by FACS analysis after double staining with 7-AAD and annexin-V (BD-Biosciences). In brief, DCs were incubated with 7-AAD and annexin-V-APC for 60 min at 4 °C, washed and analysed by flow cytometry. Double negative cells correspond to cells non-permeable to any reagent and therefore alive (Q3 region). Cells positive for annexin-V but negative for 7-AAD corresponded to early apoptotic cells (Q4 region). Double positive cells for annexin-V and 7-AAD corresponded to late apoptotic cells (Q2 region) and cells negative for annexin-V but positive for 7-AAD correspond to necrotic cells (Q1 region). Results are expressed as the mean of the percentages of late apoptotic cells ([l]{.smallcaps}-apoptosis) or early apoptotic cells (E-apoptosis) ± SD.

2.6. T-cell responses elicited by DC-LLO or DC-GAPDH vaccines {#s0040}
-------------------------------------------------------------

For delayed type hypersensitivity (DTH) analysis, Balb/c and C57BL/6 mice immunised *i*.*p* with LM^WT^ (5 × 10^3^  CFU) were inoculated 7 days later in left hind footpads with DC vaccines (10^6^ cells/mice) in the presence or absence of Advax (50 μg/ml). Non-inoculated right hind footpads served as negative controls. Positive controls of this assay included DC pre-infected *in vitro* with wild type LM (DC-LM^WT^) as previously reported ([@bb0025]). After 24 h, we measured the footpad thickness with a calliper. T cell results in the footpads are expressed in millimetres as the mean of three different experiments ± SD.

2.7. Vaccination protocols {#s0045}
--------------------------

Vaccines used were DC-LLO~91--99~, DC-LLO~296--304~, DC-LLO~189--201~, DC-LLO~189--200~, DC-LLO~190--201~, DC-GAPDH~1--15~ and DC-GAPDH~1--22~ (1 × 10^6^ cells/mice). Mice were immunised into the peritoneal cavity (*i*.*p*) (*n*  = 5) in the presence or absence of Advax (50 μg/ml) or left non-vaccinated (NV). Seven days after immunization, Balb/c and C57BL/6 mice were challenged *i*.*p* with 10^3^ and 10^4^  CFU of LM^WT^/mice, respectively, and then bled before termination ([@bb0130]). Sera were stored at − 80 °C to measure cytokines by FACS analysis using the CBA kit that measures all Th1 cytokines of a sample at the same time (Becton Dickinson, Palo Alto, CA, USA). Data were analysed using the FlowJo software (Treestar, Ashland, OR). Samples were performed in triplicate and the results are the mean ± SD of two separate experiments. ANNOVA was used for statistics with the cytokine measurements. At termination spleens and livers were homogenized and CFUs counted in blood agar plates. To measure CD4^+^ frequencies producing intracellular IFN-γ, spleen cells were cultured in 96-well plates (5 × 10^6^  cells/ml) and stimulated with GAPDH~1--15~ or GAPDH~1--22~ peptides (5 μg/ml each peptide) for 5 h in the presence of brefeldin A as previously reported ([@bb0020]). Next, cells were surface labelled for CD4, fixed and permeabilized with cytofix/cytoperm kit before staining for intracellular IFN-γ (BD Biosciences). FACS data were analysed using FlowJo software (Treestar, Ashland, OR). After sample acquisition, data were gated for CD4^+^ events, and the percentages of cells expressing IFN-γ determined according to the manufacturer\'s recommendations. Results were corrected according to the percentages of total CD4^+^ cells. Samples were tested in triplicate and the results are the mean ± SD of two separate experiments.

2.8. Frequencies of CD8^+^-LLO or GAPDH specific T cells {#s0050}
--------------------------------------------------------

To confirm the frequency of LLO~91--99~, LLO~296--304~, GAPDH~1--15~ or GAPDH~1--22~ specific CD8 T cells producing IFN-γ, we used recombinant soluble dimeric mouse H-2K^b^:Ig (for C57BL/6 mice) or H-2L^d^:Ig (for Balb/c mice) fusion proteins following the manufacturer\'s instructions (DimerX I; BD Bioscience) and as previously described ([@bb0130], [@bb0020]).

2.9. ELISA for *Listeria* peptides {#s0055}
----------------------------------

LLO~91--99~ or GAPDH~1--22~ peptides were prepared at 50 μg/ml in coating buffer (50 nM of Na~2~CO~3~ at pH 9.7) and used to coat Nunc MaxiSorp plates overnight at 4 °C. Next, plates were blocked with 1% BSA in PBS at RT for 30 min and mice sera diluted 1/200 in PBS-0.5% BSA and incubated for 1 h at RT. Mice IgM was detected with a goat anti-mouse IgM conjugated with horseradish peroxidase (0.8 μg/ml) and enzymatic reactions developed with tetramethylbenzidine in citric/acetate buffer and H~2~O~2~. Reactions were stopped with 50 μl of H~2~SO~4~ (0.8 M) and absorbances measured at 450 nm in the ELISA reader. Results were expressed as absorbance units of triplicates ± SD.

2.10. Statistical analysis {#s0060}
--------------------------

For statistical analysis, Student\'s *t* test was applied. ANOVA analysis was applied to cytokine measurements. *P*  ≤ 0.05 was considered significant. GraphPad software was used for generation of graphs.

2.11. Ethics statement {#s0065}
----------------------

This study was carried out in accordance with the Guide for the Care and Use of Laboratory Animals of the Spanish Ministry of Science, Research and Innovation. The Committee on the Ethics of Animal Experiments of the University of Cantabria approved the protocol (Permit Number: 2012/06) that follows the Spanish legislation (RD 1201/2005). All surgeries were performed under sodium pentobarbital anaesthesia, and all efforts were made to minimize suffering.

3. Results and discussion {#s0070}
=========================

3.1. Bioinformatics approach to classify *Listeria* epitopes {#s0075}
------------------------------------------------------------

The objective of this study was to design a simple experimental approach that predicted the minimal epitope requirements to load and prepare DC vaccine formulations able to protect against listeriosis. We focussed on the *Listeria* antigens LLO and GAPDH as vaccine candidates since sera from patients recovering from listeriosis recognized various peptides from these antigens ([@bb0010]; CAD and RCG unpublished results). Listeriosis is characterised by low humoral but robust T cell responses ([@bb0160]). Previously T-cell epitopes for *Listeria* vaccine design have been identified by peptide elution from MHC molecules of *Listeria*-loaded macrophages ([@bb0080], [@bb0215]). Since this approach is technically challenging, predominantly only identifies high affinity epitopes and is performed using macrophages which are less efficient at antigen presentation cells than DC, it may fail to identify many other relevant and protective *Listeria* T-cell epitopes. There is also no consensus of whether high, medium or low affinity epitopes may represent the best vaccine candidates. Bioinformatics approaches have been used in other infectious diseases to identify T-cell epitopes to include in vaccines with great success ([@bb0240], [@bb0220]). Hence we used a bioinformatics approach to screen for potential T cell epitopes in LLO and GAPDH and followed this with a modified delayed-type-hypersensitivity (DTH) test to identify T-cell epitopes with potential to provide protection against human and veterinary listeriosis. As positive controls we used five known LLO epitopes previously identified by the elution method ([@bb0080]). For T-cell epitope prediction we used IEDB, a bioinformatic prediction resource Consensus tool that combines predictions from artificial neural network (ANN), SMM and Comblib for GAPDH binding predictions ([@bb0155], [@bb0175], [@bb0210], [@bb0110]). IEDB analysis predicted that good MHC class I binders showed percentile ranks \< 10 and weak binders percentile ranks \< 100. Similarly, good MHC class II binders showed percentile thresholds \< 50, intermediate binders \< 500 and low binders \< 5000.

GAPDH~1--15~ contained four epitopes predicted to be good binders for H-2K^b^, H-2K^d^ and H-2L^d^ MHC-I molecules, and one predicted intermediate binding epitope for IA^b^ and low binder to IA^d^ (lower right image in [Fig. 1](#f0005){ref-type="fig"}A). GAPDH~1--22~ contained six epitopes predicted to be good binders to H-2K^d^ and H-2L^d^, six epitopes predicted to be intermediate binders to IA^b^ and one epitope predicted to be a low binder to IA^d^ (GAPDH binding values in [Fig. 1](#f0005){ref-type="fig"}A). These data indicated that GAPDH~1--15~ and GAPDH~1--22~ epitopes were able to bind to different MHC-I and MHC-II molecules of Balb/c and C57BL/6 mice strains.Fig. 1Methodology to predict efficient vaccine epitopes for DC vaccine formulations. (A) diagram showing the bioinformatic strategy for epitope prediction including the 3D-structure of LLO based on the recently reported crystal structure ([@bb0120]) and the relevant MHC-I and MHC-II epitopes in Balb/c and C57BL/6 mice. The purple sequence corresponds to LLO~189--201~ peptide that contains LLO~189--200~ and LLO~190--201~ MHC-II epitopes and the pink sequence corresponds to LLO~91--99~ MHC-I epitope. The green sequence corresponds to the LLO~296--394~ MHC-I epitope. On the right, the predicted 3D structure of GAPDH is shown with the GAPDH~1--22~ peptide highlighted in red. The lower image shows an enlargement of amino acids 3--15 of GAPDH~1--15~ epitope. The sequences included on the right correspond to MHC binding predictions performed with IEDB Consensus tool. (B) DCs were incubated with 50 μg/ml of peptides for 24 h and then stained with Trypan blue to assay cytotoxicity (grey bars) or incubated with 7-ADD and annexin-V to analyse apoptosis by FACS (black and white bars). An example of apoptosis read-out is shown in left panel. Cytotoxicity results are expressed as the number of cells ± SD and experiments were performed in triplicate. Apoptosis results are expressed as the mean of the percentages of early apoptotic (Q4 region), late apoptotic (Q2 region) or necrotic cells (Q1 region) ± SD (*P* \< 0.05). (C) DC from Balb/c or C57BL/6 mice were differentiated *in vitro* with 30 ng/ml of GM-CSF for 5 days, detached and positively selected using anti-mouse CD11c-coated magnetic beads and MACS separation columns. CD11c^+^ DC were loaded *ex vivo* with different peptides in the presence of 50 μg/ml of Advax: LLO~91--99~, LLO~189--200~, LLO~190--201~, LLO~189--201~, LLO~296--304~, GAPDH~1--15~ or GAPDH~1--22~ peptides (50 μg/ml) for 24 h or left unloaded (DC-CONT). Cells were washed and analysed using a FACSCanto flow cytometer. The percentages of CD11c^+^MHC-II^high^CD40^+^CD86^+^ positive cells are shown. Results are expressed as the mean ± SD of triplicate samples (*P* \< 0.05). (D) C57BL/6 (black bars) or Balb/c mice (white bars) were immunised *i.p* with 5 × 10^3^ CFU of *Listeria*/mouse for 7 days and then left hind footpads were inoculated with 1 × 10^6^ cells of different DC-LLO and DC-GAPDH vaccines or saline (NT) for 24 h in the presence of Advax (250 μg), while right hind footpads were not inoculated and served as controls. Footpad swelling was measured with a calliper and expressed as the differences in mm between left and right hind footpads. Results are expressed as the mean ± SD of three different experiments (*P* \< 0.05).

Analysis of LLO for epitopes indicated that LLO~91--99~ was predicted to be a strong binder to H-2K^d^ (0.7 values) and also a weak binder to H-2K^b^ MHC-I (67 values); LLO~296--304~ peptide was predicted to be a strong binder to H-2K^b^ (score 0.2), a weak binder to H-2K^d^ (score 32) and an intermediate binder to H-2L^d^ (score 12.5) and LLO~189--201~ was predicted to be a strong binder to IA^b^ (score 51.3) and low binder to IA^d^ (score 5326). LLO~189--200~ and LLO~190--201~ peptides were not predicted to bind to IA^d^ (score \> 10000) and to be weak binders to IA^b^ (scores 85 and 75, respectively) ([@bb0025]). All LLO epitope predictions were in agreement with the previously MHC-I and MHC-II eluted LLO epitopes ([@bb0080], [@bb0215]). However, the bioinformatic analysis also predicted new MHC binding abilities for these LLO epitopes. Hence, the LLO~91--99~ epitope previously eluted from H-2K^d^ was predicted to be a weak binder to H-2K^b^, LLO~296--304~ epitope eluted from H-2K^b^ was predicted to be a weak binder to H-2K^d^, LLO~189--201~ and LLO~190--201~ epitopes eluted from IA^b^ were predicted to be weak binders to IA^d^, and LLO~189--200~ epitope eluted from IA^d^ was predicted to be a weak binder to IA^b^. Therefore, the bioinformatics analysis identified a higher number of potential binding epitopes than the elution methods. We next studied where the predicted LLO epitopes were situated within the recently reported LLO crystal structure ([@bb0120]) PBDI: 4CDB (left image, [Fig. 1](#f0005){ref-type="fig"}A). LLO showed 4 domains (D1, D2, D3 and D4) that contained several β-sheets and α-helices with D4 being the binding domain to the phagosomal membranes. Since no crystal structure from *Listeria* GAPDH was available, we used the Automated Comparative Protein Modelling Server SWISS-MODEL available at: (<http://www.expasy-ch/swissmod/SWISS-MODEL.html>) to produce a theoretical 3D model (right image, [Fig. 1](#f0005){ref-type="fig"}A). LLO epitopes that bind to MHC-I were tight or wide loops (pink and green LLO sequences, respectively, [Fig. 1](#f0005){ref-type="fig"}A), while epitopes that bind to MHC-II contained α-helices (purple LLO sequence, [Fig. 1](#f0005){ref-type="fig"}A). A similar pattern was observed for GAPDH, with GAPDH~1--22~ and GAPDH~1--15~ epitopes that bind to MHC-I containing tight loops and epitopes that bind to MHC-II molecules containing two α-helices. According to this rule, we predicted that GAPDH~1--22~ and GAPDH~1--15~ epitopes containing tight loops and two α-helices that are able to simultaneous bind to H-2K^b^, H-2K^d^, H-2L^d^, IA^b^ and IA^d^ might be the best candidates for a T-cell based listeriosis vaccine. Next, the LLO~91--99~ epitope containing tight loops and LLO~296--304~ epitope with wide loops that both bind to MHC-I molecules and the LLO~189--201~ epitope containing two complete α-helices that bind to MHC-II molecules, were identified as good vaccine candidates as they were able to bind to MHC from both mice strains. LLO~189--200~ and LLO~190--201~ epitopes that contained one α-helix and bind to MHC-II molecules of one mice strain exclusively were classified using this algorithm as poor vaccine candidates.

3.2. Evaluation of the quality of DC vaccine formulations {#s0080}
---------------------------------------------------------

Having identified candidate vaccine epitopes we next wished to exclude any negative effects of the relevant peptides on the viability of the proposed DC vaccine vectors. DC vectors need to remain viable to fully activate T cells in the draining lymph nodes, a process that takes at least 24 h. Therefore, we examined the effect of the relevant LLO and GAPDH peptides on DC cytotoxicity and activation after 24 h of culture, the time required for DC loading with peptides ([@bb0185], [@bb0115], [@bb0225], [@bb0020]). Cytotoxicity was examined with Trypan-blue staining and apoptosis with 7-ADD and annexin-V fluorescence ([Fig. 1](#f0005){ref-type="fig"}B and [Table 1](#t0005){ref-type="table"} ) using different concentrations of LLO~91--99~, LLO~189--201~, LLO~189--200~, LLO~190--201~, LLO~296--304~, GAPDH~1--15~ or GAPDH~1--22~ peptides (0--500 μg/ml). None of the LLO or GAPDH peptides at doses of 50 μg/ml and below caused DC cytotoxicity, early (E-apo of Q4 region or E-apoptosis in black bars of [Fig. 1](#f0005){ref-type="fig"}B) or late apoptosis ([l]{.smallcaps}-apop of Q2 region or [l]{.smallcaps}-apoptosis in white bars of [Fig. 1](#f0005){ref-type="fig"}B). As the highest concentrations of peptides (500 μg/ml) were associated with slightly lower DC viability ([Table 1](#t0005){ref-type="table"}), we selected 50 μg/ml as the on-going loading concentration for our DC vaccines.Table 1Lack of cytoxicity induction of LLO and GAPDH peptides.ReagentDC viability[a](#tf0005){ref-type="table-fn"}*LLO~91--99~ (μg/ml)*5001.69 ± 0.132 × 10^6^501.79 ± 0.120 × 10^6^51.78 ± 0.113 × 10^6^0.51.79 ± 0.128 × 10^6^  *LLO~189--201~ (μg/ml)*5001.69 ± 0.132 × 10^6^501.77 ± 0.120 × 10^6^51.78 ± 0.113 × 10^6^0.51.79 ± 0.128 × 10^6^  *LLO~190--201~ (μg/ml)*5001.69 ± 0.132 × 10^6^501.76 ± 0.120 × 10^6^51.78 ± 0.113 × 10^6^0.51.79 ± 0.128 × 10^6^  *LLO~190--201~ (μg/ml)*5001.67 ± 0.132 × 10^6^501.78 ± 0.120 × 10^6^51.78 ± 0.113 × 10^6^0.51.79 ± 0.128 × 10^6^  *LLO~296--304~ (μg/ml)*5001.61 ± 0.132 × 10^6^501.77 ± 0.120 × 10^6^51.78 ± 0.113 × 10^6^0.51.79 ± 0.128 × 10^6^  *GAPDH~1--15~ (μg/ml)*5001.73 ± 0.132 × 10^6^501.78 ± 0.120 × 10^6^51.78 ± 0.113 × 10^6^0.51.79 ± 0.128 × 10^6^  *GAPDH~1--22~ (μg/ml)*5001.69 ± 0.132 × 10^6^501.78 ± 0.120 × 10^6^51.78 ± 0.113 × 10^6^0.51.79 ± 0.128 × 10^6^[^1]

An important issue for DC vaccines is their activation state, as this improves the quality of the resulting T-cell responses. Activated DCs show a characteristic CD11c^+^MHC-II^+^CD40^+^CD86^+^ phenotype that corresponds with higher vaccine efficiency ([@bb0185], [@bb0115], [@bb0225]). Peptides by themselves generally do not activate DC, although longer peptides may sometimes do so ([@bb0020]). Since LLO and GAPDH peptides differ significantly in their length, we standardised the experiment by mixing the peptides with 50 μg/ml of Advax adjuvant prior to DC loading for 24 h. Advax was included, as it has been previously shown to modulate DC activity and potently enhance CD4^+^ and CD8^+^ T cell responses to *Listeria* antigens ([@bb0200]). We also included LPS (10 ng/ml) as a classical DC activator (DC-LPS) ([@bb0115], [@bb0020]) as well as untreated control DC (DC-CONT). LPS induced the highest frequency of CD11c^+^MHC-II^high^CD40^+^CD86^+^ DC (CD11c^+^ DC) followed by GAPDH~1--22~ and GAPDH~1--15~ peptides. LLO~91--99~ induced intermediate numbers of CD11c^+^ DC. LLO~296--304~ and LLO~189--201~ peptides also induced significant numbers of CD11c^+^ DC while LLO~189--200~ and LLO~190--201~ induced no CD11c^+^ DC at all ([Fig. 1](#f0005){ref-type="fig"}C).

We applied these results to the bioinformatics predictions to identify whether there were any epitope characteristics, which predicted the highest DC activation in both mice strains. Notably, the GAPDH~1--15~ epitope that induced a high DC activation ([Fig. 1](#f0005){ref-type="fig"}C) had four MHC-I binding sequences in tight loops and one MHC-II binding sequence containing two α-helices ([Fig. 1](#f0005){ref-type="fig"}A). Intermediate DC activation occurred with the LLO~91--99~ epitope (DC-LLO~91--99~ bars in [Fig. 1](#f0005){ref-type="fig"}C) that corresponded with a tight loop (pink LLO loop in [Fig. 1](#f0005){ref-type="fig"}A) that binds to MHC-I molecules in both mice strains. Lower DC activation was observed with LLO~296--304~ epitopes (DC-LLO~296--304~ bars in [Fig. 1](#f0005){ref-type="fig"}C), which corresponded with a wide loop that binds to MHC-I molecules in both mice strains (green LLO epitopes in [Fig. 1](#f0005){ref-type="fig"}A). Very low DC activation was observed only with LLO~189--201~ epitope (DC-LLO~189--201~ bars in [Fig. 1](#f0005){ref-type="fig"}C) that corresponded with two complete α-helices that bind to MHC-II molecules in both mice strains (purple LLO epitopes in [Fig. 1](#f0005){ref-type="fig"}A). No DC activation was observed with LLO~189--200~ or LLO~190--201~ epitopes ([Fig. 1](#f0005){ref-type="fig"}C) that corresponded with one α-helix that binds exclusively to MHC-II of only one mice strain. This analysis suggests that epitopes that bind MHC-I are more likely to induce DC activation than MHC-II binders.

3.3. Quantification of T-cell responses elicited by DC-vaccine formulations {#s0085}
---------------------------------------------------------------------------

Next we sought to develop an assay to predict the DC epitopes that elicited the highest T cell responses, *in vivo*. For this purpose, we adapted a classical delayed-type-hypersensitivity (DTH) test ([@bb0150]), where DC vaccines loaded with LLO or GAPDH peptides plus Advax adjuvant (50 μg/ml) were inoculated into the foot pads of previously *Listeria*-challenged mice and the DTH response measured as the degree of footpad swelling 24 h post-inoculation ([Fig. 1](#f0005){ref-type="fig"}D). We included a positive control of DTH response, DC infected *in vitro* with wild type LM (DC-LM^WT^) that induced a high degree of footpad swelling as previously reported ([@bb0025]). In both mice strains, DC-GAPDH~1--15~ and DC-GAPDH~1--22~ vaccines generated the highest DTH responses, similar to the positive control DC-LM^WT^, followed by DC-LLO~91--99~, then DC-LLO~296--304~ and lastly DC-LLO~189--201~. DC-LLO~190--201~ induced a low DTH response only in susceptible Balb/c mice and DC-LLO~189--200~ induced no response in either strain ([Fig. 1](#f0005){ref-type="fig"}D). These results indicated that the size of the DTH responses elicited by the DC epitope vaccines formulated with Advax adjuvant, correlated well with the ability of the peptides to induce DC activation and with the initial bioinformatic predictions ([Fig. 1](#f0005){ref-type="fig"}B--C). The removal of Advax adjuvant from the DC vaccine formulations reduced all DTH results \~ 5-fold but the Advax adjuvant did not modify the controls (data not shown), confirming that its action was *via* enhancement of antigen-specific T-cell responses. This is consistent with enhancement of antigen-specific T-cell responses observed with Advax adjuvant in other contexts such as when combined with influenza, hepatitis B or SARS coronavirus vaccines ([@bb9000], [@bb0100], [@bb0205]).

Next, we tested whether the strong DTH results for specific DC vaccines correlated with a Th1 cytokine response, as reflected in the supernatants of DC loaded with the different LLO and GAPDH peptides in the presence of Advax adjuvant as in [Fig. 1](#f0005){ref-type="fig"}A. We observed that for both mouse strains, DC-GAPDH~1--22~, DC-GAPDH~1--15~ and DC-LLO~91--99~ vaccines induced the highest TNF-α levels followed by DC-LLO~296--304~. DC-LLO~189--201~, DC-LLO~190--201~ and DC-LLO~189--200~ vaccines induced no TNF-α ([Table 2](#t0010){ref-type="table"} ). Only DC-GAPDH~1--22~ and DC-GAPDH~1--15~ induced significant levels of IL-12 in both mice strains, with IL-12 having been shown to correlate with protective vaccine responses against listeriosis ([@bb0115] and [@bb0020]). DC-LLO~91--99~ vaccines produced low but significant levels of IL-12 in both mice strains whereas DC-LLO~296--304,~ DC-LLO~189--201~, DC-LLO~190--201~ and DC-LLO~189--200~ induced no detectable IL-12 levels ([Table 2](#t0010){ref-type="table"}). Thus, only the DC epitopes originally predicted by bioinformatic analysis to be the best CD8 T-cell epitopes and which produced the highest DTH responses *in vivo* were associated with significant IL-12 production by DC.Table 2Th1 cytokines production by DC vaccines loaded with peptides in the presence of Advax.Epitope[a](#tf0010){ref-type="table-fn"}Th1-cytokines (pg/ml)^b^CytokinesBalb/cC57BL/6LLO~91--99~TNF-α1495 ± 1021475 ± 118IL-124.5 ± 0.1\*0.45 ± 0.05LLO~296--304~TNF-α315 ± 0.9310 ± 0.9IL-120 ± 00 ± 0LLO~190--201~TNF-α15 ± 0.710 ± 0.8IL-120.11 ± 00.12 ± 0.04LLO~189--200~TNF-α10 ± 0.811 ± 0.7IL-120 ± 00 ± 0LLO~189--201~TNF-α25 ± 0.920 ± 0.9IL-120 ± 00 ± 0GAPDH~1--22~TNF-α1635 ± 1001721 ± 113IL-1225 ± 0.8\*24 ± 0.8\*GAPDH~1--15~TNF-α1515 ± 1201510 ± 138IL-1224 ± 0.8\*22 ± 0.9\*[^2][^3]

3.4. Validation of proposed methods of epitope prediction for listeriosis vaccines {#s0090}
----------------------------------------------------------------------------------

Next, to verify the above predictions, susceptible Balb/c and resistant C57BL/6 mice were immunized with DC-LLO~91--99~, DC-LLO~296--304~, DC-LLO~189--200~, DC-LLO~190--201~, DC-LLO~189--201~, DC-GAPDH~1--15~, or DC-GAPDH~1--22~ together with Advax (50 μg/ml) or were left non-vaccinated (NV). Mice were immunized *i*.*p* with a single dose of vaccine and 7 days later were administered a *Listeria* challenge (see [Methods](#s0010){ref-type="sec"} section for procedures). Five days post-challenge, all mice were bled, sacrificed and spleens recovered to count *Listeria* CFU and analyse immune cell populations ([Fig. 2](#f0010){ref-type="fig"}A and [Table 3](#t0015){ref-type="table"} ). DC-GAPDH~1--15~ and DC-GAPDH~1--22~ provided the greatest protection in both Balb/c and C57BL/6 mice (\~ 97 and 99%, respectively) ([Fig. 2](#f0010){ref-type="fig"}A). DC-LLO~91--99~ also conferred significant protection in both Balb/c and C57BL/6 mice (90 and 93%, respectively). DC-LLO~296--304~ vaccine conferred strong protection in C57BL/6 mice (\~ 90%) ([Fig. 2](#f0010){ref-type="fig"}A) but only intermediate levels of protection in Balb/c mice (\~ 60%) (white bars in [Fig. 2](#f0010){ref-type="fig"}A). DC-LLO~189--200~, DC-LLO~190--201~, and DC-LLO~189--201~ vaccines conferred no significant protection in either strain (2 and 5%, respectively). Vaccination efficiency was associated with normal spleen size (images of DC-GAPDH~1--15~ vaccine recipients shown in [Fig. 2](#f0010){ref-type="fig"}A) compared with enlarged spleens (images of NV mice in [Fig. 2](#f0010){ref-type="fig"}A) and granulomatous livers of non-vaccinated mice (data not shown). We also evaluated several immunological parameters induced by the most protective DC vaccines. DC-GAPDH~1--15~ and DC-GAPDH~1--22~ vaccines were found to induce the highest frequencies of IFN-γ-producing CD8^+^ T cells in both C57BL/6 and Balb/c mice (4.0--4.2%, respectively) followed by DC-LLO~91--99~ vaccine with 3.0% frequency as assessed by FACS using H2-K^b^:Ig-peptide dimers or 2.16% frequency using H2-L^d^:Ig-peptide dimers (right plot in [Fig. 2](#f0010){ref-type="fig"}B). DC-LLO~296--304~ vaccine induced very low 0.87% CD8^+^ T cell frequencies in C57BL/6 mice and undetectable frequencies in Balb/c mice (DC-LLO~296--304~ bars in [Fig. 2](#f0010){ref-type="fig"}B). Only DC-GAPDH~1--15~ and DC-GAPDH~1--22~ vaccines induced detectable numbers of IFN-γ producing peptide-specific CD4^+^ T cells (1.05 and 1.76%, respectively) ([Fig. 2](#f0010){ref-type="fig"}B show C57BL/6 data, values in Balb/c were 1.05 and 1.76%). In summary, our results with DC-GAPDH vaccines confirmed that CD8^+^ T cell responses were more relevant than CD4^+^ T cell responses for *Listeria* protection. GAPDH~1--15~ and GAPDH~1--22~ peptides presented high numbers of MHC-I binding epitopes in listeriosis resistant and sensible mice, explaining DC-GAPDH vaccines induced similar CD8^+^ T cell responses and Th1-cytokines in both mice strains.Fig. 2Experimental validation of epitope predictions with vaccination assays. DC vaccines were tested for their immunogenicity and ability to protect against listeriosis. (A) C57BL/6 (black bars) or Balb/c (white bars) mice were vaccinated *i.p* with different DC vaccine vectors (1 × 10^6^ cells). DC-CONT, DC-GAPDH~1--15~, DC-GAPDH~1--22~, DC-LLO~91--99~, DC-LLO~296--304~, DC-LLO~189--200~, DC-LLO~189--201~ or DC-LLO~190--201~ in the presence of Advax (50 μg/ml) or left not vaccinated (NV) (n = 5 mice/group) and 7 days later were challenged *i.p* with 10^3^ CFU LM (for Balb/c mice) or 10^4^ CFU LM (for C57BL/6 mice). Results of spleen homogenates are expressed as CFU (mean ± SD) and obtained from triplicate samples of three independent experiments (*P* \< 0.01). Images correspond to spleens of non-vaccinated mice (NV) showing splenomegaly *versus* DC-GAPDH~1--15~ vaccinated C57BL/6 mice. (B) C57BL/6 or Balb/c mice were vaccinated and then challenged with LM as in A and examined for specific GAPDH T-cell responses by intracellular cytokine staining (lower plots). Homogenates were stimulated 5 h with GAPDH~1--15~ or GAPDH~1--22~ peptides then intracellular cytokine staining performed. Histograms show the frequency of GAPDH~1--15~ (left lower plot) and GAPDH~1--22~-specific CD4^+^ T cells (right lower plot) and IFN-γ producers in C57BL/6 spleen homogenates. Experiments were performed in triplicate and results are expressed as mean ± SD (*P* \< 0.05). To measure the frequencies of CD8^+^ GAPDH-specific immune responses (right plots), splenocytes from vaccinated mice were incubated with recombinant dimeric H-2K^b^:Ig (black bars) or H-2L^d^:Ig (white bars) fusion proteins loaded with LLO~91--99~, LLO~296--304~, GAPDH~1--15~ or GAPDH~1--22~ peptides, respectively. The staining cocktail contained the dimeric fusion protein loaded with the peptides, CD8 and IFN-γ antibodies. CD8^+^ cells were gated for anti-IFN-γ staining (% Gated dimer-CD8) to calculate the frequencies of CD8^+^-GAPDH~1--15~ or CD8^+^-GAPDH~1--22~ restricted cells and IFN-γ producers. Results were expressed as the mean ± SD of triplicates (*P* \< 0.05). (C) Levels of pro-inflammatory cytokines MCP-1, TNF-α or IFN-γ were analysed in mouse sera from DC-vaccinated and LM challenged mice as in A using the CBA kit (BD Biosciences) by flow cytometry (see Material and Methods). Upper plot correspond to cytokine measurements of C57BL/6 mice and lower plot to Balb/c mice. Results expressed as cytokine concentration (pg/ml) of mean ± SD, *P* \< 0.05. (D), IL-12 levels of sera from A measured with the CBA kit and expressed as cytokine concentration (pg/ml) of mean ± SD, *P* \< 0.05.Table 3B cell responses elicited by DC-vaccines in the presence of Advax.Vaccine[a](#tf0015){ref-type="table-fn"}Anti-peptide IgM antibodies[b](#tf0020){ref-type="table-fn"}LLO~91--99~GAPDH~1--22~Control0.156 ± 0.050.163 ± 0.04NV0.517 ± 0.021.021 ± 0.02DC-GAPDH~1--22~0.712 ± 0.022.011 ± 0.05DC-LLO~91--99~0.583 ± 0.031.276 ± 0.02  Vaccine[a](#tf0015){ref-type="table-fn"}Spleen markers[c](#tf0025){ref-type="table-fn"}CD19^+^CD4^+^CD8^+^CD11c^+^-CD86^+^Control19 ± 0.57 ± 0.38 ± 0.20.5 ± 0.02NV15 ± 0.518 ± 0.617 ± 0.526 ± 0.8DC-GAPDH~1--22~15 ± 0.326 ± 0.428 ± 0.570 ± 0.7DC-LLO~91--99~15 ± 0.27 ± 0.227 ± 0.370 ± 0.6[^4][^5][^6]

Antibody production and B cell responses seemed to play no role in listeriosis ([@bb0160]). However, antibodies against LLO seemed to participate in neutralization of *Listeria* growth ([@bb0065]). Here, we confirmed no variation in B cell numbers among non-vaccinated (NV), vaccinated mice (DC vaccines) or non-infected control mice (control) with similar percentages of CD19^+^ positive cells (Spleen markers rows in [Table 3](#t0015){ref-type="table"}). Nevertheless, DC-GAPDH~1--22~ (DC-GAPDH~1--22~ rows in [Table 3](#t0015){ref-type="table"}) or DC-GAPDH~1--15~ vaccines (data not shown) produced high levels of anti-GAPDH~1--22~ IgM antibodies compared to non-vaccinated mice (NV) that correlated with an increase in the percentages of CD4^+^ T cells. DC-LLO~91--99~ vaccinated mice produced no significant levels of anti-LLO~91--99~ IgM antibodies compared to NV and presented low percentages of CD4^+^ T cells (DC-LLO~91--99~ rows in [Table 3](#t0015){ref-type="table"}). These data strongly suggested that vaccines conferring the highest protection in listeriosis induced prominent antigen-specific T cell responses and promoted also antigen-specific B cell responses, suggesting a collaborative role of B and T cell responses in listeriosis protection ([@bb0065], [@bb0005], [@bb0020], [@bb0025]).

Finally, vaccination with DC-GAPDH~1--15~, DC-GAPDH~1--22~ or DC-LLO~91--99~ vaccine induced high levels of MCP-1, TNF-α and IFN-γ in both mice strains whereas DC-LLO~296--304~ vaccine induced only intermediate levels of TNF-α in C57BL/6 mice (DC-LLO~296--304~ bars in [Fig. 2](#f0010){ref-type="fig"}C). Only DC-GAPDH~1--15~ and DC-GAPDH~1--22~ vaccines induced high IL-12 levels, post-challenge, in both mice strains (right plot in [Fig. 2](#f0010){ref-type="fig"}C). DC-LLO~91--99~ vaccine induced low but significant levels of IL12 in both mice strains ([@bb0115], [@bb0020]). Thus the *Listeria* T-cell epitope prediction algorithm described in the methods was validated *in vivo* and shown to predict vaccine effectiveness after *Listeria* vaccination of low and high susceptibility mice. Advax adjuvant was confirmed to be important to induction of a potent *Listeria* antigen specific T-cell response, consistent with its ability to enhance vaccine protection in other models including influenza, where it similarly enhanced CD4^+^ and CD8^+^ T-cell responses and Th1 cytokine production ([@bb9000]). The present results confirm that Advax adjuvant has the ability to induce MHC I cross-presentation of *Listeria* antigens thereby resulting in activation of *Listeria*-specific CD8 T cells, although the mechanism by which it might induce cross-presentation is currently unknown. One possibility currently under investigation is that Advax induces cross-presentation *via* activation of CD4^+^ T helper cells that signal to upregulate cross-presentation pathways in antigen presenting cells. When considering design of *Listeria* vaccines, a major advantage of Advax over other potential T-cell adjuvants is its lack of toxicity as evidenced by data from preclinical studies ([@bb0140], [@bb0055], [@bb0060], [@bb0135], [@bb0125], [@bb0180], [@bb0205], [@bb0015], [@bb0070], [@bb0095], [@bb0100]) as well as human clinical trials ([@bb0085], [@bb0090]).

4. Conclusions {#s0095}
==============

New methods of T-cell epitope screening would greatly assist design of DC vaccine formulations, including for protection against listeriosis. Here we have developed a method for DC vaccine design that combines bioinformatic prediction of MHC binding epitopes with 3D structural predictions and DC functional assays utilising Advax, a potent T-cell adjuvant, to amplify the signal. Using these methodologies, we successfully predicted *Listeria* epitopes that when incorporated in DC vaccines and administered to either Balb/c or C57BL/6 mice were able to confer protection against *Listeria* challenge. Peptides binding at least four MHC-I molecules with high affinity due to tight loops and also containing a weaker MHC-II binding epitope containing two α-helices, elicited the highest DC activation, the strongest DTH immune responses and the highest production of IL-12. These properties conferred the greatest protection in mouse strains at either high or low susceptibility to listeriosis. The GAPDH~1--15~ epitope possessed these minimal requirements and proved to have similar protective efficacy to the longer GAPDH~1--22~ epitope. This methodology might help to design new human and veterinary vaccines against listeriosis, an area of need given the increasing incidence of this disease in European countries ([@bb0165], [@bb0230], [@bb0170]). The methodology used in this study to predict the best T-cell epitopes for vaccine design, might be useful in design of DC vaccines against other infectious diseases, and notably the protective GAPDH~1--15~ epitope showed 98% homology with *S. pneumonia* and *Streptococcus pyogenes* ([@bb0005]).
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[^1]: *In vitro* cytoxicity assayed using DC incubated with different doses of peptides (0--500 μg/ml) for 24 h and then stained with Trypan blue. Results are expressed as the number of viable cells ± SD and experiments were performed in triplicates (*P* \< 0.05).

[^2]: Asterisks show the IL-12 significant levels.

[^3]: Levels of pro-inflammatory TNF-α and IL-12 cytokines were analysed in sera of different DC vaccinated Balb/c or C57BL/6 mice in the presence of Advax adjuvant (50 μg/ml) by CBA. Results are expressed as cytokine concentration (pg/ml of mean ± SD, *P* \< 0.05).

[^4]: C57BL/6 (Table) or Balb/c (data not shown) mice were vaccinated in the presence of Advax (50 μg/ml) with DC-GAPDH~1--22~ or DC-LLO~91--99~ vaccines or non-vaccinated (NV). 7 days post-vaccination, vaccinated and NV mice were infected with 5 × 10^3^ CFU of LM^WT^ for 5 days. Control mice were non-vaccinated and non-infected. Next, mice were sacrificed and sera collected and stored at − 80 °C. Spleens were homogenized for further analysis.

[^5]: Sera from vaccinated, non-vaccinated or control mice were thawed and examined peptide-ELISA as described in [Methods](#s0010){ref-type="sec"} section. Reactions were developed with goat anti-mouse IgM and absorbances analysed at 450 nm. Results are the mean of triplicates ± SD.

[^6]: Cell surface markers were examined in spleens of vaccinated, non-vaccinated or control mice after incubation with different antibodies conjugated with fluorochromes and analyse by FACS. Results corresponded to the mean of the percentages of positive cells ± SD.
